- Growing interest in the company’s innovative DehydraTECH
drug delivery platform from large global corporations - Lexaria’s strategy to be listed on a nationally recognized U.S. exchange will help the company access a significantly larger audience of investors
- Lexaria has 16 patents with another 60 pending worldwide and is the only company to hold a patent for improved delivery of all non-psychoactive cannabinoids
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, has achieved virtually everything it set out to do in 2019 and has even bigger plans for 2020 that include achieving higher revenue and being listed on a major U.S. exchange, according to CEO Chris Bunka in a strategic update to shareholders (http://cnw.fm/hcA4X). While its shares remain “dramatically undervalued” at the moment, Bunka said, the company boasts a successful 2019 during which it signed different partnerships and agreements for use of its innovative DehydraTECH drug delivery platform.
The revolutionary drug delivery platform accelerates human intestinal cell absorption of bioactive substances administered without the need for inhalational dosing, co-administration with sugars or sweeteners, and other unhealthy practices. It is applicable to a wide variety of bioactive substances, including cannabis and…
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
